► 14:10 Data Updates From ASCO 2021 Oncology @amerseburger and @ERPlimackMD discuss data presented at #ASCO2021 on #urothelialcarcinoma.
► 1:49 Association Between Angiotensin Blockade and Response to PD-1/L1 Inhibition in Metastatic Urothelial Carcinoma Oncology @sonpavde, of @DanaFarber_GU, discusses the effects of #angiotensin blockade on #PD-1/L1 inhibition in #metastatic #urothelialcarcinoma.
► 5:48 Therapeutic Effects of WST11 Vascular-Targeted Photodynamic Therapy Urology @lucasmnnogueira, of @sloan_kettering, discusses the #safety and #efficacy of WST11 vascular-targeted #photodynamic therapy.
► 12:15 Case Discussion: 49-Year-Old Male With UTUC Oncology @MattMossanen; @sonpavde; Steven L Chang, MD, MS; Michelle S. Hirsch, MD, PhD; and Mark A. Preston, MD, PhD, discuss a patient with #UTUC.
► :50 Updated Guidelines for Treatment of Non-Metastatic MBIC to be Presented at AUA Meeting Bladder Cancer Content Hub The AUA has teamed up with ASCO, ASTRO, and SUO to provide new guidelines for non-metastatic MBIC treatment.
► 1:06 Pelvic Radiotherapy Provides Long-Term Palliation In Patients With Bladder and Prostate Cancer Bladder Cancer Content Hub A recent study investigated utilizing palliative pelvic radiotherapy for metastatic bladder or prostate cancer patients.
► 0:59 Multiple Clinical Trials of Immunotherapies for Recurrent and Metastatic Cancers Are Reaching Maturation Bladder Cancer Content Hub There are currently a large number of ongoing trials examining immunotherapies for bladder, kidney, prostate, and renal cancers.
► 1:09 Accurate Staging of Bladder Cancer Proves Crucial for Improving Disease Treatment Bladder Cancer Content Hub Muscle-invasive bladder cancer (MIBC) is considered to be T2 stage due to tumor invasion into the muscle wall.
► 1:13 Super-Responders vs. Hyper-Progression with Immunotherapy Bladder Cancer Content Hub The trial revealed a linear correlation between higher tumor burden and anti-PD1 and anti-programmed death ligand (PD-L1) checkpoint inhibitors, explained as the immune system responding to reactivation.
